Nobel Biocare Holding AG (Nobel Biocare Holding AG) Net Change in Cash : $51.0 Mil (TTM As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Nobel Biocare Holding AG Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Nobel Biocare Holding AG's Net Change in Cash for the six months ended in Dec. 2013 was $51.0 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2013 was $51.0 Mil.

Nobel Biocare Holding AG Net Change in Cash Historical Data

The historical data trend for Nobel Biocare Holding AG's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nobel Biocare Holding AG Net Change in Cash Chart

Nobel Biocare Holding AG Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Net Change in Cash

Get a 7-Day Free Trial

114.45

-24.52

-173.84

51.93

50.97

Nobel Biocare Holding AG Semi-Annual Data
	Dec02	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
Net Change in Cash	Get a 7-Day Free Trial							114.45	-24.52	-173.84	51.93	50.97

Nobel Biocare Holding AG Net Change in Cash Calculation

Nobel Biocare Holding AG's Net Change in Cash for the fiscal year that ended in Dec. 2013 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	106.616	+	-14.759	+	-40.888	+	0
	=	51.0

Nobel Biocare Holding AG's Net Change in Cash for the quarter that ended in Dec. 2013

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 106.616 + -14.759 + -40.888 + 0

= 51.0

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2013 was $51.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nobel Biocare Holding AG Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Nobel Biocare Holding AG's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Nobel Biocare Holding AG (Nobel Biocare Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nobel Biocare Holding AG (OTCPK:NBHGF) » Definitions » Net Change in Cash

Comparable Companies

BSP:FLRY3 TSE:3360 SHSE:603222 TSE:8086 IRTC XTER:GXI SZSE:002382 XSWX:YPSN TSE:7716 STAA AVNS TSE:7730 ASX:ANN GKOS MMSI TSE:3046 SZSE:002294 TSE:7780 ASX:NAN XKLS:7113

Traded in Other Exchanges

N/A

Address

Website

http://www.nobelbiocare.com

Nobel Biocare Holding AG was founded in 2002 in Zurich,Switzerland. The Company offers dental implant systems, high-precision individualized prosthetics and CAD/CAM systems, diagnostics, treatment planning, guided surgery solutions and biomaterials. Its segments include Implant system products and Individualized products. Its geographical segments include United States, Japan, Switzerland, and Other Countries.

Nobel Biocare Holding AG (Nobel Biocare Holding AG) Headlines

From GuruFocus

Mario Gabelli Comments on Nobel Biocare Holding AG
By Vera Yuan Vera Yuan • 10-28-2014

The new NobelProcera� Zirconia Implant Bridge simplifies the partnership between clinicians and technicians
By PRNewswire PRNewswire • 02-08-2021